These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 31324754)

  • 1. Inhibition of the BET family reduces its new target gene IDO1 expression and the production of L-kynurenine.
    Tian CQ; Chen L; Chen HD; Huan XJ; Hu JP; Shen JK; Xiong B; Wang YQ; Miao ZH
    Cell Death Dis; 2019 Jul; 10(8):557. PubMed ID: 31324754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclooxygenase-2 (COX-2) inhibition constrains indoleamine 2,3-dioxygenase 1 (IDO1) activity in acute myeloid leukaemia cells.
    Iachininoto MG; Nuzzolo ER; Bonanno G; Mariotti A; Procoli A; Locatelli F; De Cristofaro R; Rutella S
    Molecules; 2013 Aug; 18(9):10132-45. PubMed ID: 23973990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
    Sartor GC; Powell SK; Brothers SP; Wahlestedt C
    J Neurosci; 2015 Nov; 35(45):15062-72. PubMed ID: 26558777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
    Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
    Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of upregulated indoleamine 2, 3-dioxygenase 1 by interferon γ gene transfer on interferon γ-mediated antitumor activity.
    Watcharanurak K; Zang L; Nishikawa M; Yoshinaga K; Yamamoto Y; Takahashi Y; Ando M; Saito K; Watanabe Y; Takakura Y
    Gene Ther; 2014 Sep; 21(9):794-801. PubMed ID: 24919418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon-γ induces a tryptophan-selective amino acid transporter in human colonic epithelial cells and mouse dendritic cells.
    Bhutia YD; Babu E; Ganapathy V
    Biochim Biophys Acta; 2015 Feb; 1848(2):453-62. PubMed ID: 25450809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRD4 bimodal binding at promoters and drug-induced displacement at Pol II pause sites associates with I-BET sensitivity.
    Khoueiry P; Ward Gahlawat A; Petretich M; Michon AM; Simola D; Lam E; Furlong EE; Benes V; Dawson MA; Prinjha RK; Drewes G; Grandi P
    Epigenetics Chromatin; 2019 Jul; 12(1):39. PubMed ID: 31266503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of inflammatory genes in decidual cells: Involvement of the bromodomain and extra-terminal family proteins.
    Ajgaonkar S; Hirst JJ; Norris M; Zakar T
    PLoS One; 2023; 18(3):e0280645. PubMed ID: 36897880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic Targeting of Histone H3K27 Acetylation/BRD4-dependent Induction of ALDH1A3 for Early-phase Drug Tolerance of Gastric Cancer.
    Lee J; Mashima T; Kawata N; Yamamoto N; Morino S; Inaba S; Nakamura A; Kumagai K; Wakatsuki T; Takeuchi K; Yamaguchi K; Seimiya H
    Cancer Res Commun; 2024 May; 4(5):1307-1320. PubMed ID: 38669046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.
    Roberts TC; Etxaniz U; Dall'Agnese A; Wu SY; Chiang CM; Brennan PE; Wood MJA; Puri PL
    Sci Rep; 2017 Jul; 7(1):6153. PubMed ID: 28733670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
    Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
    Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells.
    Coudé MM; Braun T; Berrou J; Dupont M; Bertrand S; Masse A; Raffoux E; Itzykson R; Delord M; Riveiro ME; Herait P; Baruchel A; Dombret H; Gardin C
    Oncotarget; 2015 Jul; 6(19):17698-712. PubMed ID: 25989842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro cytokine licensing induces persistent permissive chromatin at the Indoleamine 2,3-dioxygenase promoter.
    Rovira Gonzalez YI; Lynch PJ; Thompson EE; Stultz BG; Hursh DA
    Cytotherapy; 2016 Sep; 18(9):1114-28. PubMed ID: 27421739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy.
    Gomes B; Driessens G; Bartlett D; Cai D; Cauwenberghs S; Crosignani S; Dalvie D; Denies S; Dillon CP; Fantin VR; Guo J; Letellier MC; Li W; Maegley K; Marillier R; Miller N; Pirson R; Rabolli V; Ray C; Streiner N; Torti VR; Tsaparikos K; Van den Eynde BJ; Wythes M; Yao LC; Zheng X; Tumang J; Kraus M
    Mol Cancer Ther; 2018 Dec; 17(12):2530-2542. PubMed ID: 30232146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity.
    Liu X; Shin N; Koblish HK; Yang G; Wang Q; Wang K; Leffet L; Hansbury MJ; Thomas B; Rupar M; Waeltz P; Bowman KJ; Polam P; Sparks RB; Yue EW; Li Y; Wynn R; Fridman JS; Burn TC; Combs AP; Newton RC; Scherle PA
    Blood; 2010 Apr; 115(17):3520-30. PubMed ID: 20197554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
    Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
    Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Indoleamine 2,3-Dioxygenase Activity in
    Virok DP; Raffai T; Kókai D; Paróczai D; Bogdanov A; Veres G; Vécsei L; Poliska S; Tiszlavicz L; Somogyvári F; Endrész V; Burián K
    Front Cell Infect Microbiol; 2019; 9():192. PubMed ID: 31249813
    [No Abstract]   [Full Text] [Related]  

  • 19. Indoleamine 2,3-Dioxygenase 1 Inhibitor-Loaded Nanosheets Enhance CAR-T Cell Function in Esophageal Squamous Cell Carcinoma.
    Shao J; Hou L; Liu J; Liu Y; Ning J; Zhao Q; Zhang Y
    Front Immunol; 2021; 12():661357. PubMed ID: 33828565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
    Chen B; Alvarado DM; Iticovici M; Kau NS; Park H; Parikh PJ; Thotala D; Ciorba MA
    Cancer Immunol Res; 2020 Apr; 8(4):451-464. PubMed ID: 32127391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.